TEVA - テバ・ファ―マス―ティカル・インダストリ―ズ ()


   Teva to Host Conference Call to Discuss Fourth Quarter 2020 Financial Results and 2021 Financial Guidance at 8 a.m. ET on February 10, 2021  2021/01/08 20:01:00 Business Wire
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that it will issue a press release on its fourth quarter and full year 2020 financial results, as well as on its financial guidance for 2021, on Wednesday, February 10, 2021 at 7:00 a.m. ET. Following the release, Teva will conduct a conference call and live webcast on the same day, at 8:00 a.m. ET. In order to participate, please dial the following numbers (at least 10 minutes before th
   Global Rituximab Biosimilars Market Report 2020: Market is Expected to Recover and Reach $2.62 Billion in 2023 at a CAGR of 13.85% - Forecast to 2030 -  2021/01/08 12:16:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Rituximab Biosimilars Global Market Report 2020-30: COVID-19 Growth and Change" report has been added to's offering. Rituximab Biosimilars Global Market Report 2020-30: COVID 19 Growth and Change provides the strategists, marketers and senior management with the critical information they need to assess the global rituximab biosimilars market. Major players in the rituximab biosimilars market are Pfizer Inc., Mylan Inc., Amgen Inc., Teva Pharm
   Teva to Present at the 39th Annual J.P. Morgan Healthcare Conference  2021/01/07 21:00:00 Business Wire
TEL AVIV, Israel--(BUSINESS WIRE)--Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) today announced that President & CEO Kåre Schultz will present at the 39th Annual J.P. Morgan Healthcare Conference in San Francisco, California on Wednesday, January 13, 2021. The presentation will begin at 8:20 A.M. Eastern Time. To access a live webcast of the presentation, visit Teva’s Investor Relations website at An archived version of the presentation will be availabl
   Teva and MedinCell Announce Positive Results for Registration Trial of Investigational Extended-Release Subcutaneous Injectable Risperidone for Patients with Schizophrenia  2021/01/07 13:00:00 Business Wire
TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the RISE study – The Risperidone Subcutaneous Extended-Release Study), a Phase 3 clinical trial designed to evaluate the efficacy of TV-46000/mdc-IRM (risperidone extended-release injectable suspension for subcutaneous use) as a treatment for patients with schizophrenia. Trial enrollment was open to pa
   Simplivia Healthcare buys diagnostics co Novamed  2021/01/05 15:33:18 Globes English
FIMI controlled Simplivia, whioch develops devices for the safe administration of hazardous drugs, operates out of the former Teva factory in Kiryat Shmona.
   Pfizer, GSK & Others Quietly Hike Prices On 100s Of Drugs  2020/12/31 23:30:00 Zero Hedge
Pfizer, GSK & Others Quietly Hike Prices On 100s Of Drugs With just hours to go until the new year, Reuters reports that a group of the world's largest drug companies is preparing to hike drug prices, defying President Trump to issue a last-minute rebuke, as he has done in the past. Drugmakers including Pfizer Inc, Sanofi SA, and GlaxoSmithKline Plc plan to raise U.S. prices on more than 300 drugs in the United States on Jan. 1, according to drugmakers and data analyzed by healthcare research firm 3 Axis Advisors. The hikes come as drugmakers are reeling from effects of the COVID-19 pandemic, which has reduced doctor visits and demand for some drugs. They are also fighting new drug price cutting rules from the Trump administration, which would reduce the industry’s profitability. The companies kept their price increases at 10% or below, and the largest drug companies to raise prices so far, Pfizer and Sanofi, kept nearly all of their increases 5% or less, 3 Axis said. 3 Axis is a consulting firm that works with pharmacists groups, health plans and foundation on drug pricing and supply chain issues.
   2020 Ongoing Marketplace Opportunities in Oncology Biosimilars Market- Celltrion Inc., Teva Pharmaceutical Industries Ltd, Samsung Bioepis Co. Ltd., Intas Pharmaceuticals Ltd and more  2020/12/30 10:40:54 OpenPR
It is our aim to provide our readers with report for Oncology Biosimilars Market, which examines the industry during the period 2020 – 2026. One goal is to present deeper insight into this line of business in this document. The
   Consumer Healthcare Market Is Booming Worldwide | Sun Pharma, Takeda Pharmaceuticals, Teva Pharmaceuticals  2020/12/30 07:58:14 OpenPR
Global Consumer Healthcare Market Insights, Forecast to 2025 is latest research study released by HTF MI evaluating the market, highlighting opportunities, risk side analysis, and leveraged with strategic and tactical decision-making support. The study provides information on market trends and
   Global Narcolepsy Treatment Market Research Insights, COVID-19 Impact and Future Trends By 2026||Top Leaders-BIOPROJET, Hikma Pharmaceuticals PLC, Amneal Pharmaceuticals LLC, Teva Pharmaceutical Industries  2020/12/29 18:50:43 OpenPR
The Narcolepsy Treatment market report is a window to the industry which explains what market definition, classifications, applications, engagements and market trends are. This study also analyzes the market status, growth rate, future trends, market drivers, opportunities and challenges, risks
   Pharmaceutical Pfizer, AstraZeneca and Amazon to build new innovation laboratory in Israel  2020/12/28 21:27:00 Entrepreneur
The Innovation Lab will have a budget of 10 million dollars, will be located in the Rehovot Science Park and will begin operations in 2021. The partners will include the pharmaceutical companies Teva and Merck, as well as the Biotech Fund.
   Artificial Intelligence For Modern Drug Development Market Expected to Witness High Growth over the Forecast Period 2020 - 2025 | Bayer AG, Teva, Imperial College London, Roche, Lundbeck  2020/11/27 12:49:44 OpenPR
A comprehensive research study titled Artificial Intelligence For Modern Drug Development market has recently been added by Healthcare Intelligence Markets to its extensive repository. The statistical data is compiled by means of qualitative and quantitative research methodologies which help to
   How A lot Is Teva Pharmaceutical Industries Restricted (NYSE:TEVA) Paying Its CEO?  2020/11/26 16:53:37 Fintech Zoom
How A lot Is Teva Pharmaceutical Industries Restricted (NYSE:TEVA) Paying Its CEO? -
   EU fines Teva €60.5m for "pay for delay" pact  2020/11/26 15:37:00 Globes English
The agreement was with Cephalon, which Teva subsequently acquired, concerning sleep disorder treatment modanifil.
   EU Fines Teva, Cephalon For Pay-for-delay Drug Deal  2020/11/26 13:03:15 CNN-News18
The European Commission has fined pharmaceutical company Teva and its now subsidiary Cephalon 60.5 million euros ($72 million) for agreeing to delay a cheaper generic version of Cephalon's sleep disorder medicine.
   Disruptive Behavior Disorder (DBD) Medication Market - Promius Pharma LLC, Shire PLC, Johnson and Johnson, Mylan N.V., Novartis AG, Teva Pharmaceuticals Industries Ltd., GlaxoSmithKline plc, Sun Pharmaceutical Industries Ltd., Lupin Ltd., and Eli Lilly an  2020/11/25 10:16:34 OpenPR
An informative study on the Disruptive Behavior Disorder (DBD) Medication Market from 2020-2027 has lately released for the database of Coherent Market Insights that helps by making business conclusions and shape the future of the organizations. Individual analysis of top